FDA Hold Persists as Evenamide Death Imbalance Is Disclosed

Company Newron Pharmaceuticals Event Type FDA clinical hold rationale and safety disclosure Modality Small molecule (selective voltage-gated sodium-channel blocker) Asset Evenamide Target Voltage-gated sodium channels (glutamate modulation) Disease Area Treatment-resistant schizophrenia Summary Newron disclosed the FDA’s written rationale for maintaining the U.S. clinical hold on…